Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.

  • Authors : Bobrowicz M; Department of Immunology, Medical University of Warsaw, Warsaw, Poland.; Kusowska A

Subjects: Antigens, CD20*/Antigens, CD20*/Antigens, CD20*/immunology ; Antigens, CD20*/Antigens, CD20*/Antigens, CD20*/metabolism ; Antigens, CD20*/Antigens, CD20*/Antigens, CD20*/genetics

  • Source: Oncoimmunology [Oncoimmunology] 2024 Jun 04; Vol. 13 (1), pp. 2362454. Date of Electronic Publication: 2024 Jun 04 (Print Publication: 2024).Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Clinical advances in immunotherapy for immune-mediated glomerular diseases.

  • Authors : Tang B; Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China.; Yang X

Subjects: Immunotherapy*; Humans ; Rituximab/Rituximab/Rituximab/therapeutic use

  • Source: Clinical and experimental medicine [Clin Exp Med] 2023 Dec; Vol. 23 (8), pp. 4091-4105. Date of Electronic Publication: 2023 Oct 27.Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Editorial & Opinion

Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.

  • Authors : Epperla N; Division of Hematology, Department of Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA. .; Welkie RL

Subjects: Immunotherapy* ; Lymphoma*; Humans

  • Source: Journal of hematology & oncology [J Hematol Oncol] 2023 May 08; Vol. 16 (1), pp. 49. Date of Electronic Publication: 2023 May 08.Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722

Record details

×
Academic Journal

Cerebellum/liver index in pretherapeutic 18F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance.

  • Authors : Godard F; Médecine Nucléaire, Institut Godinot, Reims, France.; Durot E

Subjects: Cerebellum*/Cerebellum*/Cerebellum*/diagnostic imaging ; Immunotherapy* ; Liver*/Liver*/Liver*/diagnostic imaging

  • Source: Medicine [Medicine (Baltimore)] 2022 Feb 04; Vol. 101 (5), pp. e28791.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.

  • Authors : Matasar MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: .; Dreyling M

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Immunotherapy/Immunotherapy/Immunotherapy/*methods ; Lymphoma, B-Cell/Lymphoma, B-Cell/Lymphoma, B-Cell/*drug therapy

  • Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2021 Nov; Vol. 21 (11), pp. e886-e894. Date of Electronic Publication: 2021 Jul 02.Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.

  • Authors : LeBlanc FR; Department of Medicine, Pennsylvania State University College of Medicine and Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.; Co-first authors.

Subjects: Epigenesis, Genetic* ; Immunotherapy* ; Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/Lymphoma, Mantle-Cell*/drug therapy

  • Source: Oncotarget [Oncotarget] 2022 Aug 16; Vol. 13, pp. 986-1002. Date of Electronic Publication: 2022 Aug 16 (Print Publication: 2022).Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.

  • Authors : Ma J; Department of Neurology, Beijing Shunyi Hospital, NO.3 Guangming South Street, Shunyi District, Beijing 101300, China; Department of Neurology, Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing 100160, China.

Subjects: Azathioprine/Azathioprine/Azathioprine/*therapeutic use ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Immunotherapy/Immunotherapy/Immunotherapy/*methods

  • Source: Journal of neuroimmunology [J Neuroimmunol] 2022 Feb 15; Vol. 363, pp. 577790. Date of Electronic Publication: 2021 Dec 16.Publisher: Elsevier/North-Holland Country of Publication: Netherlands NLM ID: 8109498 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.

  • Authors : Lin JS; Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Wang DY

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/Immune Checkpoint Inhibitors/*adverse effects ; Immunotherapy/Immunotherapy/Immunotherapy/*methods

  • Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Oct; Vol. 8 (2).Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Binding mechanisms of therapeutic antibodies to human CD20.

  • Authors : Kumar A; Membrane Protein Mechanisms Unit, Institut Pasteur, 75015 Paris, France.; Membrane Protein Mechanisms Group, European Institute of Chemistry and Biology, University of Bordeaux, 33607 Pessac, France.

Subjects: Immunotherapy*; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*chemistry ; Antigen-Antibody Complex/Antigen-Antibody Complex/Antigen-Antibody Complex/*chemistry

  • Source: Science (New York, N.Y.) [Science] 2020 Aug 14; Vol. 369 (6505), pp. 793-799.Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Immunotherapy for Refractory Autoimmune Encephalitis.

  • Authors : Yang J; Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.; Liu X

Subjects: Plasma Exchange*; Autoimmune Diseases/Autoimmune Diseases/Autoimmune Diseases/*therapy ; Immunologic Factors/Immunologic Factors/Immunologic Factors/*pharmacology Autoimmune limbic encephalitis

  • Source: Frontiers in immunology [Front Immunol] 2021 Dec 16; Vol. 12, pp. 790962. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2021).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
  • 1-10 of  1,113 results for ""RITUXIMAB""